This study will assess the ability of AIN457 to attenuate the increase in airway neutrophils that is seen following ozone exposure. Healthy subjects will be treated with AIN457, placebo, or oral corticosteroid and the response to a subsequent ozone exposure will be evaluated.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Enrollment
24
Novartis Investigative Site
Großhansdorf, Germany
Total neutrophil cell count in 106/mL in induced sputum
Time frame: Day 16
Serum total IL-17A
Time frame: Day 1- Day 120
Percentage neutrophil cell count in induced sputum
Time frame: Day 16
Safety and tolerability. Safety assessments will include vital signs, electrocardiograms (ECG), spirometry, pulse oximetry, immunogenicity and adverse events (AEs)
Time frame: Day 1-Day 120
Airway function (FEV1, FVC, and FEF25-75)
Time frame: 4h, 24h, and 48h after the start of the ozone exposure
Serum AIN457 pharmacokinetics (PK)
Time frame: Day1-Day 120
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.